Beneficial Ownership Report · SCHEDULE 13G/A
uniQure N.V.
QURENASDAQEQUITYCurrent
Beneficial Ownership Report
Structured filing — SCHEDULE 13G/A
primary_doc.xml
Amendment · This filing reports the amendment as submitted.
Subject company
- Company
- uniQure N.V.
- Company CIK
- 0001590560
- Street
- Paasheuvelweg 25a
- Street (continued)
- 1105 BP Amsterdam
- City
- The Netherlands
- State / country code
- XX
- Postal code
- 00000
Statement details
- Amendment number
- 1
- Security class
- Ordinary Shares, par value 0.05
- Event date
- 09/30/2026
- Rule designation
- Rule 13d-1(b)
Reporting person 1
- Name
- JPMORGAN CHASE & CO.
- Citizenship / organization
- DE
- Reporting person type
- HC
- Aggregate amount owned
- 5,951,794.0
- Percent of class
- 8.5
- Sole voting power
- 5,654,307.0
- Shared voting power
- 1.0
- Sole dispositive power
- 5,943,150.0
- Shared dispositive power
- 1.0
Item 1
Issuer
uniQure N.V.
Principal executive office address
Paasheuvelweg 25a 1105 BP Amsterdam The Netherlands
Item 2
Citizenship
DE
Filing person
JPMORGAN CHASE & CO.
Principal business or residence address
270 Park Avenue,,New York, NY 10017
Item 3
Not applicable indication
N
Type of filing person
HC
Item 4
Percent of class
8.5
Amount beneficially owned
5951794
Sole voting power
5654307
Shared voting power
1
Sole dispositive power
5943150
Shared dispositive power
1
Item 5
Not applicable indication
Y
Ownership of 5% or less
N
Item 6
Not applicable indication
N
Ownership on behalf of another person
Not Applicable
Item 7
Not applicable indication
N
Subsidiaries
JPMorgan Asset Management (UK) Limited; JPMorgan Chase Bank, National Association; J.P. Morgan Investment Management Inc.; J.P. Morgan Wealth Management Solutions Inc.
Item 8
Not applicable indication
N
Group members
Not Applicable
Item 9
Not applicable indication
N
Item 10
Not applicable indication
N
Certifications
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
Signature 1
- Reporting person
- JPMORGAN CHASE & CO.
- Signed
- Rachel Tsvaygoft
- Title
- Vice President
- Date
- 10/16/2026
Company context
uniQure is delivering on the promise of gene therapy - single treatments with potentially curative results. The approvals of uniQure’s gene therapy for hemophilia B - an historic achievement based on more than a decade of research and clinical development - represent a major milestone in the field of genomic medicine and ushers in a new treatment approach for patients living with hemophilia. uniQure is now advancing a pipeline of proprietary gene therapies for the treatment of patients with Huntington's disease, refractory temporal lobe epilepsy, Fabry disease, and other severe diseases. www.uniQure.com